Edgewise Therapeutics' EDG-7500 Shows Significant Progress in Heart Disease Treatment
Boulder, Wednesday, 2 April 2025.
Edgewise Therapeutics reports a 71% reduction in heart obstruction with EDG-7500, promising improved treatment for hypertrophic cardiomyopathy and boosting potential investment interest.
Breakthrough Trial Results
Edgewise Therapeutics (NASDAQ: EWTX) has unveiled promising results from its Phase 2 CIRRUS-HCM trial for EDG-7500, marking a significant advancement in treating hypertrophic cardiomyopathy (HCM). The trial, involving 29 participants, demonstrated that patients receiving the 100mg dose experienced a 71% reduction in resting left ventricular outflow tract gradients [1][3]. The treatment showed remarkable efficacy across both obstructive and nonobstructive HCM patients, with 78% of participants improving by at least one NYHA functional class [3].
Patient Outcomes and Safety Profile
The drug’s impact on quality of life has been particularly noteworthy, with patients receiving the 100mg dose showing a mean increase of 23 points in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score [4]. Safety data indicates EDG-7500 was well-tolerated, with no participants experiencing left ventricular ejection fraction drops below 50% [3]. The most common side effects were mild to moderate, primarily including dizziness (27.6%) and upper respiratory tract infection (17.2%) [4].
Market Response and Future Plans
Following these positive results, Edgewise Therapeutics has announced a $200 million common stock offering priced at $20.13 per share [7]. Wall Street analysts maintain an optimistic outlook, with price targets ranging from $30 to $56, suggesting a potential upside of 137.21% [2]. The company plans to initiate Phase 3 trials in the first half of 2026, with proceeds from the stock offering supporting both the EDG-7500 development and other pipeline products [3][7].